We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bioventix Plc | LSE:BVXP | London | Ordinary Share | GB00B4QVDF07 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -50.00 | -1.41% | 3,500.00 | 1,888 | 14:57:57 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 3,450.00 | 3,550.00 | 3,550.00 | 3,500.00 | 3,550.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 13.61M | 8.1M | 1.5543 | 22.52 | 184.93M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:11:06 | O | 260 | 3,450.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 06/12/2024 | 07:00 | UK RNS | BioVentix PLC Result of AGM |
| 04/12/2024 | 15:34 | UK RNS | BioVentix PLC Holding(s) in Company |
| 22/11/2024 | 15:56 | UK RNS | BioVentix PLC Director/PDMR Shareholding |
| 08/11/2024 | 07:57 | UK RNS | BioVentix PLC Notice of AGM |
| 31/10/2024 | 07:00 | UK RNS | BioVentix PLC Director/PDMR Shareholding |
| 28/10/2024 | 11:59 | ALNC |  Bioventix "pleased" as annual profit rises and sales grow |
| 28/10/2024 | 07:00 | UK RNS | BioVentix PLC Results for the year ended 30 June 2024 |
| 25/10/2024 | 09:37 | UK RNS | BioVentix PLC Holding(s) in Company |
| 16/10/2024 | 12:51 | UK RNS | BioVentix PLC Holding(s) in Company |
| 30/4/2024 | 06:00 | UK RNS | BioVentix PLC Director/PDMR Shareholding |
Bioventix (BVXP) Share Charts1 Year Bioventix Chart |
|
1 Month Bioventix Chart |
Intraday Bioventix Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 30/10/2024 | 14:34 | Bioventix - Sheep Antibodies | 1,614 |
| 08/11/2016 | 13:07 | ShareSoc Supper in Brighton | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:11:07 | 3,450.00 | 260 | 8,970.00 | O |
| 15:03:39 | 3,525.00 | 56 | 1,974.00 | O |
| 14:57:21 | 3,500.00 | 75 | 2,625.00 | O |
| 14:57:01 | 3,500.00 | 75 | 2,625.00 | O |
| 14:46:07 | 3,500.00 | 32 | 1,120.00 | O |
| Top Posts |
|---|
Posted at 29/10/2024 06:48 by multibagger Good morning all :)My post has landed badly - unfortunate. I understand the science and can see where tech in this area is heading and invest with 5-10 year timeframes at a minimum unless the story changes. Though antibodies will have their niche role they will diminish in importance, there is a potential Eastman Kodak v digital, video cassette v digital streaming moment here. Some may prefer not to see what is coming and what was a cash cow could stagnate or diminish - investing is about looking forwards. I am not here to try and persuade you to invest anywhere :) I have got into APTA fairly recently, so looking at their historical share price at 117p is immaterial to my investment decision. Good luck and we can take stock in about 3-5 years time as to the relative share prices of BVXP and APTA if the AIM market still exists and we are all around. I wish you well - investing is not a zero sum game but an infinite one. We make our choices and decide what to buy and when to exit. A note from a very successful, happy and cheerful dimwit :) For the record: Share prices on the day of the post, 28 Oct 2024 APTA: 0.225p BVXP : £ 32.50 |
Posted at 28/10/2024 09:32 by indiestu The price action this morning screams positive to me, lots of buyers coming in when the price was taken down first thing. Quite a pleasing reversal so far. This could have been a final wash out before the next big rally. I liked this section of the results. Revenues are peanuts at present but the growth could be significant. It must be very difficult to shake people out of their shares in Bioventix.'Our research into Tau antibodies and Alzheimer's diagnostics continues to progress and we are delighted that our early work has now translated into a modest revenue stream from antibodies now entering commercial manufacture. Our commercial policy is to supply initial evaluation samples of antibodies free of charge. If antibodies perform well on prototype assay systems at our IVD customers and additional supplies are ordered, these are charged at regular prices and such repeat sales have generated revenues during the year. These revenues are not only additive but also indicate that our antibodies could feature in future commercial assays. In addition to our conventional IVD customers, we have also supplied antibodies to specialist platform customers, for example Quanterix Corporation who specialise in assays for the research market. The research market is established earlier than more regulated tests for routine clinical use and it is pleasing that royalty revenues from such activities have already been established. Total Tau revenues for the year were above our expectation at £155k'. |
Posted at 25/10/2024 08:35 by sharesoc Join ShareSoc for the Growth Company Seminar/Webinar – 27th November 2024 (London)On 27th November, ShareSoc is hosting a Growth Company Seminar in London featuring presentations from: Bioventix (BVXP) – Peter Harrison, CEO Polar Capital Global Financials Trust plc (PCFT) – Tom Dorner, Fund Manager Altona Rare Earths (REE) – Dr. Cedric Simonet, CEO Wheaton Precious Metals (WPM) – Randy Smallwood, President & CEO Schedule: 5:00 pm start 25-minute presentations 15-minute Q&A after each presentation Networking over drinks and buffet Attend in-person or watch virtually. Register Here: |
Posted at 13/9/2024 12:51 by melody9999 Sharw 1583 re communication that has always been the case. But in the last few weeks I think the possible Budget changes to IHT AIM and CGT increases have caused the share price retrace.BVXP is perhaps the best example of a great AIM share that has a large proportion of long term holders. Sadly I think concerns about the Budget has caused some of them to reduce. I have a medium size holding, have not sold any .... and will be looking to add if we see continued weakness. |
Posted at 13/9/2024 11:31 by sharw The problem with this company is that it does not communicate with either the market or its shareholders except when it has to. So, in the last twelve months we have had just two trading statements - the interim and final results.It is obliged to inform the market if its financial situation diverges from brokers' expectations. (Rule of thumb is that it must do so if 10% out). BVXP did this once - on 14/9/22 when it warned that results would be "significantly ahead of market expectations". Results are on Mon 28th October |
Posted at 23/5/2024 08:39 by gsbmba99 “Building on the foundation our team developed last year, Quanterix is entering a new innovation and product delivery phase,” said Masoud Toloue, Chief Executive Officer of Quanterix. “We’ve announced the first of several new assays that could re-define the way Tau is measured from the brain versus peripheral sources. We will continue to lead in bringing novel biomarker detection solutions to market for the research community; developing tests to study and enable the early detection of neuro-pathologies such as Multiple Sclerosis, Parkinson’s, and Alzheimer’s disease.” ( A bit unclear but maybe brain-derived tau?Page 6 of the accompanying results presentation makes it clear Mr. Toloue is indeed talking about Quanterix introducing an assay for brain-derived tau in Q2 ( Could this be a first commercial success for the UGOT/BVXP BD-tau antibody? |
Posted at 25/3/2024 10:39 by melody9999 I see Cavendish have raised their price target to 5900p from 4400p in Oct 23. Will be happy to see the BVXP once again climb above the Cavendish target price! |
Posted at 21/2/2024 10:34 by stepone68 Share price starting with a '5' now. Certainly feels like it is popular at the moment. |
Posted at 12/2/2024 12:16 by maddox A Director's sale, if well handled, can work to enhance the share price - you sell sufficient shares to entice in a new Financial Investor - but not sell them as big a holding as they which to have. They then need to buy in the open market, creating demand and supporting the share price whilst they accumulate their desired holding.Can't say whether this is the case here but looks likely. |
Posted at 30/10/2023 18:10 by maddox I remember seeing an RNS from Norges Bank that had leant a tranch of shares. This explained the dip in the firm's share price - only to see the share price rebound strongly.... followed by another RNS from Norges Bank that had increased their holding. Presumably, they had picked up the shorters shares at a lower price and been paid for the privilege. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
